The Randomized Controlled Clinical Trial of Kushen Injection

Inclusion Criteria: * Before the start of the study, All patients have been fully understood the reseach and the must sign the informed consent * To be aged from 18 to 75 years old, both gender * The lung cancer diagnosis must be proved by pathology * According to RECIST (version 1.1), At least 1 objectively measurable Tumor lesion (iconography: CT, MRI), the assessable lesion can be measured accurately, maximum diameter more than at least 10mm (Malignant lymph nodes on CT scans short diameter less than at least 15 mm) * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 * Lung function FEV1 more than at least 1Land more than 50% A normal value * The function of each organ is basically normal :ANC more than 1.5\*10\^9/L, Platelet count more than 100\*10\^9/L, Hb more than 9.0g/dl, BIL at normal level or less than 1.5\*ULN, AST (SGOT), ALT (SGPT) less than 2.5\*ULN(less than 5\*ULN, if with liver metastases), SCr less than 1.5\*ULN * The expected survival tme must more than 6 months. Exclusion Criteria: * Lung or mediastinal have received radiotherapy before or ever treated with Compound Kushen Injection within 2weeks * Pregnancy or lactation women * Patients with severe, uncontrolled organic lesions or infection, such as decompensated heart, lung, kidney failure can lead to tolerance of chemotherapy - Participating or within the last 30 days participated in other clinical trials * Hypersensitiveness to any kind of trial regime * Had a history of serious Psychological or Psychiatric disorders, Drug addiction or Alcohol dependence * Estimating the compliance of patients to participate in this clinical trial is insufficient.